Comparative Pharmacology
Head-to-head clinical analysis: ARESTOCAINE HYDROCHLORIDE W LEVONORDEFRIN versus MEPIVACAINE HYDROCHLORIDE W LEVONORDEFRIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ARESTOCAINE HYDROCHLORIDE W LEVONORDEFRIN versus MEPIVACAINE HYDROCHLORIDE W LEVONORDEFRIN.
ARESTOCAINE HYDROCHLORIDE W/ LEVONORDEFRIN vs MEPIVACAINE HYDROCHLORIDE W/ LEVONORDEFRIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Articaine hydrochloride is a local anesthetic of the amide type that blocks voltage-gated sodium channels in nerve cell membranes, inhibiting the generation and conduction of nerve impulses. Levonordefrin is a sympathomimetic vasoconstrictor that acts on alpha-adrenergic receptors to produce local vasoconstriction, reducing absorption of the anesthetic and prolonging its effect.
Local anesthetic that blocks voltage-gated sodium channels in neuronal membranes, preventing propagation of action potentials and transmission of pain signals.
For local anesthesia: 1-5 mL of 2% solution (20 mg/mL) with levonordefrin 1:20,000, infiltrated locally; maximum single dose: 3.5 mg/kg (not to exceed 200 mg total).
Dental infiltration or nerve block: 1-2 cartridges (36-72 mg mepivacaine; 0.009-0.018 mg levonordefrin) of 2% solution with 1:20,000 levonordefrin; maximum dose: 4.4 mg/kg mepivacaine (not to exceed 300 mg) per appointment.
None Documented
None Documented
Articaine: approximately 1-2 hours (terminal half-life). Levonordefrin: not separately reported; vasoconstrictor effect duration supports anesthetic action. Clinical context: half-life is short, reflecting rapid metabolism by plasma esterases; clinical duration of anesthesia is prolonged by levonordefrin.
Terminal elimination half-life is approximately 2-3 hours in adults. In neonates, half-life is prolonged (8-10 hours due to immature hepatic function). Clinical context: Short half-life reduces risk of systemic accumulation with repeated doses.
Renal: primarily as metabolites (hydroxy derivatives) and unchanged drug; approximately 90% eliminated in urine as metabolites, <5% unchanged. Biliary/fecal: minor, <10%.
Mepivacaine is primarily metabolized in the liver via N-demethylation and hydroxylation. Less than 5% is excreted unchanged in urine. Hepatic clearance accounts for >90% of elimination; renal excretion of metabolites accounts for the remainder. Fecal elimination is minimal (<2%).
Category C
Category C
Local Anesthetic with Vasoconstrictor
Local Anesthetic with Vasoconstrictor